Israel - English - Ministry of Health

neopharm ltd - fluorouracil; salicylic acid - solution - salicylic acid 10 g / 100 g; fluorouracil 0.5 g / 100 g - wart and anti-corn preparations - common warts ( special form : plantar warts, on areas of the sole of the foot that are subjected to pressure), plane juvenile warts of the extremities.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - salicylic acid; lactic acid - cutaneous solution - 16.7 %w/w + 15.0 percent weight/weight - wart and anti-corn preparations

Malta - English - Medicines Authority

beecham group plc 980 great west road, brentford, middlesex, tw8 9gs, united kingdom - lactic acid, salicylic acid - cutaneous solution - lactic acid 15 % (w/w) salicylic acid 16.7 % (w/w) - other dermatological preparations

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

legacy pharmaceuticals switzerland gmbh - nitric acid 70%, glacial acetic acid, oxalic acid dihydrate, lactic acid 90%, copper nitrate trihydrate - solution for external use - 580,66mg/ml+41,08mg/ml+57,32mg/ml+ 4,55mg/ml+0,048mg/ml

United States - English - NLM (National Library of Medicine)

eci pharmaceuticals llc - isometheptene mucate (unii: 8o120fds6p) (isometheptene - unii:y7l24thh6t) - isometheptene mucate 65 mg

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals, llc - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - palonosetron hydrochloride injection is indicated in adults for prevention of: as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride is recommended even where the incidence of postoperative nausea and/or vomiting is low. palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: palonosetron hydrochloride is contraindicated in patients known to have hypersensitivity to palonosetron [see warnings and precautions (5.1) ]. risk summary there are no available data on palonosetron hydrochloride use in pregnant women to inform a drug-associated risk. in animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral palonosetron hydrochloride during the period of organogen

United States - English - NLM (National Library of Medicine)

the wellness center for research and education, inc. - berberis vulgaris root bark (unii: 1th8q20j0u) (berberis vulgaris root bark - unii:1th8q20j0u), thuja occidentalis leaf (unii: 0t0dqn8786) (thuja occidentalis leaf - unii:0t0dqn8786), apis mellifera (unii: 7s82p3r43z) (apis mellifera - unii:7s82p3r43z), pulsatilla vulgaris (unii: i76kb35jev) (pulsatilla vulgaris - unii:i76kb35jev), delphinium staphisagria seed (unii: 00543ap1jv) (delphinium staphisagria seed - unii:00543ap1jv), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), bry - for temporary relief of irritation. for temporary relief of irritation.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and

Ireland - English - HPRA (Health Products Regulatory Authority)

cuxson gerrard & company ltd - salicylic acid - medicated plaster - 40 percent weight/weight - wart and anti-corn preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

cuxson gerrard & company ltd - salicylic acid - medicated plaster - 40 percent weight/weight - wart and anti-corn preparations